These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Molecular Modeling Study of c-KIT/PDGFRα Dual Inhibitors for the Treatment of Gastrointestinal Stromal Tumors. Keretsu S; Ghosh S; Cho SJ Int J Mol Sci; 2020 Nov; 21(21):. PubMed ID: 33153146 [TBL] [Abstract][Full Text] [Related]
3. Structure-guided identification of potent inhibitors of ROS1 kinase for therapeutic development against non-small cell lung cancer. Khan MS; Altwaijry N; Al-Bagmi MS; Alafaleq NO; Alokail MS; Shahwan M; Shamsi A J Biomol Struct Dyn; 2024 May; 42(8):3837-3847. PubMed ID: 37254309 [TBL] [Abstract][Full Text] [Related]
4. A shift of dynamic equilibrium between the KIT active and inactive states causes drug resistance. Srikakulam SK; Bastys T; Kalinina OV Proteins; 2020 Nov; 88(11):1434-1446. PubMed ID: 32530065 [TBL] [Abstract][Full Text] [Related]
5. Phytoconstituents and Medicinal Plants for Anticancer Drug Discovery: Computational Identification of Potent Inhibitors of PIM1 Kinase. Anjum F; Mohammad T; Almalki AA; Akhtar O; Abdullaev B; Hassan MI OMICS; 2021 Sep; 25(9):580-590. PubMed ID: 34448628 [TBL] [Abstract][Full Text] [Related]
6. Discovery of promising B lymphocyte kinase inhibitors using structure-guided virtual screening. Yang S; Wahab S; Almoyad MAA; Chen Y; Kalam N; Khalid M J Biomol Struct Dyn; 2024 Aug; 42(13):7054-7064. PubMed ID: 37688373 [TBL] [Abstract][Full Text] [Related]
7. Identification of Phytochemicals Targeting c-Met Kinase Domain using Consensus Docking and Molecular Dynamics Simulation Studies. Aliebrahimi S; Montasser Kouhsari S; Ostad SN; Arab SS; Karami L Cell Biochem Biophys; 2018 Jun; 76(1-2):135-145. PubMed ID: 28852971 [TBL] [Abstract][Full Text] [Related]
9. Discovery and optimization of natural-based nanomolar c-Kit inhibitors via in silico and in vitro studies. Nada H; Kim S; Godesi S; Lee J; Lee K J Biomol Struct Dyn; 2023; 41(21):11904-11915. PubMed ID: 36636795 [TBL] [Abstract][Full Text] [Related]
10. In silico exploration of c-KIT inhibitors by pharmaco-informatics methodology: pharmacophore modeling, 3D QSAR, docking studies, and virtual screening. Chaudhari P; Bari S Mol Divers; 2016 Feb; 20(1):41-53. PubMed ID: 26416560 [TBL] [Abstract][Full Text] [Related]
11. Identifying novel therapeutic inhibitors to target FMS-like tyrosine kinase-3 (FLT3) against acute myeloid leukemia: a molecular docking, molecular dynamics, and DFT study. Islam MR; Osman OI; Hassan WMI J Biomol Struct Dyn; 2024; 42(1):82-100. PubMed ID: 36995071 [TBL] [Abstract][Full Text] [Related]
12. Structure-based identification of potential inhibitors of ribosomal protein S6 kinase 1, targeting cancer therapy: a combined docking and molecular dynamics simulations approach. Alam A; Khan MS; Mathur Y; Sulaimani MN; Farooqui N; Ahmad SF; Nadeem A; Yadav DK; Mohammad T J Biomol Struct Dyn; 2024 Jul; 42(11):5758-5769. PubMed ID: 37365756 [TBL] [Abstract][Full Text] [Related]
13. Identification of a Multitargeted Tyrosine Kinase Inhibitor for the Treatment of Gastrointestinal Stromal Tumors and Acute Myeloid Leukemia. Lin WH; Wu SY; Yeh TK; Chen CT; Song JS; Shiao HY; Kuo CC; Hsu T; Lu CT; Wang PC; Wu TS; Peng YH; Lin HY; Chen CP; Weng YL; Kung FC; Wu MH; Su YC; Huang KW; Chou LH; Hsueh CC; Yen KJ; Kuo PC; Huang CL; Chen LT; Shih C; Tsai HJ; Jiaang WT J Med Chem; 2019 Dec; 62(24):11135-11150. PubMed ID: 31721578 [TBL] [Abstract][Full Text] [Related]
14. Virtual screening, pharmacokinetics, molecular dynamics and binding free energy analysis for small natural molecules against cyclin-dependent kinase 5 for Alzheimer's disease. Shukla R; Singh TR J Biomol Struct Dyn; 2020 Jan; 38(1):248-262. PubMed ID: 30688165 [TBL] [Abstract][Full Text] [Related]
15. Molecular mechanism of D816X mutation-induced c-Kit activation and -mediated inhibitor resistance in gastrointestinal stromal tumor. Jiang H; Shao W; Wang Y; Xu R; Zhou L; Mu X J Mol Graph Model; 2018 Sep; 84():189-196. PubMed ID: 30015051 [TBL] [Abstract][Full Text] [Related]
16. Uncovering potential CDK9 inhibitors from natural compound databases through docking-based virtual screening and MD simulations. Singh P; Kumar V; Jung TS; Lee JS; Lee KW; Hong JC J Mol Model; 2024 Jul; 30(8):267. PubMed ID: 39012568 [TBL] [Abstract][Full Text] [Related]
17. The role of small molecule Kit protein-tyrosine kinase inhibitors in the treatment of neoplastic disorders. Roskoski R Pharmacol Res; 2018 Jul; 133():35-52. PubMed ID: 29704617 [TBL] [Abstract][Full Text] [Related]
18. A multitier virtual screening study of phytoconstituents as Myeloid Cell Leukemias 1 inhibitors. Liu W; Khalid M; Wahab S; Faizan Siddiqui M; Hasan Khan S; Sadiq M; Khatoon Z J Biomol Struct Dyn; 2024 Jul; 42(10):5219-5228. PubMed ID: 37418235 [TBL] [Abstract][Full Text] [Related]
19. Identification of mitogen-activated protein kinase 7 inhibitors from natural products: Combined virtual screening and dynamic simulation studies. Alharbi B; Alnajjar LI; Alhassan HH; Khan S; Jawaid T; Abdullaev BS; Alshammari N; Yadav DK; Adnan M; Shamsi A J Mol Recognit; 2024 Jan; 37(1):e3067. PubMed ID: 37956676 [TBL] [Abstract][Full Text] [Related]
20. Discover Novel Covalent Inhibitors Targeting FLT3 through Hybrid Virtual Screening Strategy. Hu S; Liu J; Chen S; Gao J; Zhou Y; Liu T; Dong X Biol Pharm Bull; 2021; 44(12):1872-1877. PubMed ID: 34853270 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]